Your AI-Trained Oncology Knowledge Connection!
BOSTON-Raising 3D conformal radiation therapy doses for localized prostate cancer produced far less toxicity than expected in a nine-center cooperative study reported at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).
Prostate cancer is the second leading cause of cancer-related deaths among men in Texas. From 1990 to 1997, the average annual number of prostate cancer-related deaths in Texas was 1900, and the average annual death rate was 20.9 per
Angiogenesis is essential to prostate cancer progression. The first study of antiangiogenic therapy in patients with locally advanced prostate cancer at The University of Texas M. D. Anderson Cancer Center showed that
Can tart cherries alleviate cancer pain? Does prayer help heal African-American women with breast cancer? To answer such questions, Johns Hopkins Medicine has been awarded a 5-year, $7.8 million grant from the National Institutes of Health
Over the past several years, the clinical presentation of prostate cancer has evolved so that more patients than ever before are presenting with clinically localized disease. However, a significant number of men continue to
BETHESDA, Md-The National Cancer Institute has released a summary of published data derived so far from the Prostate Cancer Outcomes Study (PCOS), which seeks to determine the effect of various therapies for primary invasive prostate cancer on patients’ quality of life.
BETHESDA, Md-Grants totaling $12.7 million have been awarded to five institutions for new research initiatives in breast and prostate cancer. The National Cancer Institute under its SPORE program (Specialized Program of Research Excellence) will fund the projects. The money will pay for the first year of the 5-year projects. Awards went to:
BOSTON-Short-term hormone therapy may benefit patients with localized intermediate- and high-risk prostate cancer, according to three retrospective studies presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
BOSTON-Combining long-term hormone therapy with radiation therapy for locally advanced prostate cancer significantly improves local progression, disease-free survival, freedom from distant metastasis, and biochemical control, according to results of a phase III clinical trial presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
A second omnibus health-care bill-this one called the Public Health Improvement Act (H.R. 2498)-was passed quietly at the end of the 2000 session, with a prostate cancer section included. That section was originally a free-standing bill called
Over the past several years, the clinical presentation of prostate cancer has evolved so that more patients than ever before are presenting with clinically localized disease. However, a significant number of men continue to
Over the past several years, the clinical presentation of prostate cancer has evolved so that more patients than ever before are presenting with clinically localized disease. However, a significant number of men continue to
The fastest growing segment of the US population is the group over the age of 65 years. In the next 30 years, this group will comprise over 20% of the population. Because 60% of all cancers occur in this age group, there will be an expected rise in the total cancer burden.
The world’s population is aging. Older age is associated with an increase in the incidence of cancer, especially cancer of the breast, lung, prostate, and colon. The management of older patients with cancer is biased by the
Over the past several years, the clinical presentation of prostate cancer has evolved so that more patients than ever before are presenting with clinically localized disease. However, a significant number of men continue to
NEW YORK-To help support spouses of prostate cancer patients, New York Yankees manager Joe Torre, a prostate cancer survivor, and his wife Ali are helping to launch “Two Against One: Couples Battling Prostate Cancer.” This multimedia program helps spouses become more informed about prostate cancer and empowers them to advocate for improved outcomes for their husbands.
ATLANTA-High-intensity, focused ultrasound (HIFU) delivered through a rectal probe was highly successful at burning away localized prostate cancer, Christian Chaussy, MD, reported at the American Urological Association 2000 Annual Meeting.
PHILADELPHIA-Evidence for the role of diet in the etiology of prostate cancer is mounting and with it, the possibility that nutritional factors can help prevent the disease, Demetrius Albanes, MD, said at the annual meeting of the Society of Nutritional Oncology Adjuvant Therapy. Dr. Albanes is a senior investigator with the Cancer Prevention Studies Branch of the National Cancer Institute.
NEW YORK, New York-Estramustine (Emcyt) can potentiate the effects of taxanes, and the combination might offer a new therapeutic possibility for patients with hormone-resistant prostate cancer. The combination is being tested in clinical trials described by Anne Hamilton, MD, of New York University Medical Center, at a clinical investigators’ workshop sponsored by the University of Texas M. D. Anderson Cancer Center and Pharmacia Oncology.
A potential new treatment under development for prostate cancer may offer clinical advantages, researchers reported at the annual meeting of the American Urological Association in Atlanta.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.
NEW ORLEANS-In a phase II study, weekly docetaxel (Taxotere) significantly reduced bone pain and PSA levels in men with hormone-refractory prostate cancer, and these results led to enhanced quality of life. Lead investigator Tomasz Beer, MD, of Oregon Health Sciences University, reported the results at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Clinical results demonstrate the potential of an investigational drug, exisulind (Aptosyn), to delay the need for androgen-deprivation therapy in men who have undergone prostatectomy and are at risk of prostate cancer recurrence. Detailed
